Summit Trail Advisors’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Summit Trail Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$620K	Buy	18,286 +4,756	+35%	+$158K	0.01%	1159
2026 Q1	$408K	Buy	+13,530	New	+$435K	0.01%	1226
2018 Q1	–	Sell	-2,029	Closed	-$42K	–	1525
2017 Q4	$42K	Buy	+2,029	New	+$30.5K	0.01%	860

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $21.3B AUM 44.31% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.8B AUM 42.86% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $59.1B AUM 41.96% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $16.3B AUM 54.64% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Lingotto Investment Management London, United Kingdom $5.74B AUM 42.24% 1-Year Est. Return

Summit Trail Advisors's TEVA Position: Q2 2026 in Review

Summit Trail Advisors increased its Teva Pharmaceutical Industries Limited (TEVA) stake by 35% in Q2 2026, buying an estimated $158K and bringing the position to 18,286 shares worth $620K. The position accounts for 0.01% of the portfolio, ranked #1159.

Summit Trail Advisors first reported a position in TEVA in Q4 2017 and has held it in 3 quarters since. 679 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Summit Trail Advisors held 18,286 shares of Teva Pharmaceutical Industries Limited worth $620K as of Q2 2026.
Summit Trail Advisors bought 4,756 Teva Pharmaceutical Industries Limited shares in Q2 2026, an estimated $158K.
Teva Pharmaceutical Industries Limited made up 0.01% of Summit Trail Advisors's portfolio in Q2 2026, its #1159 holding.
Summit Trail Advisors first reported a position in Teva Pharmaceutical Industries Limited in Q4 2017 and has held it in 3 quarters since.
679 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.